Loading…
Employees: 83
Size Kitazato (368A.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $317M, the 1333rd largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥1,248 on 6 Nov 2026.
Performance Over six months the shares fell 9.2%, against -25.9% for the median peer and +1.8% for the Japan market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 9.3% over the last twelve months (peer median -4.4%); the operating margin is 52.1% (peer median 4.9%).
Valuation It trades at 12.0× forward earnings against a peer median of 20.2× (cheapest of 4).
Price implies For today's price to make sense, revenue must grow about -17% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -22 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 56.5 points above its cost of capital (5.0% WACC).
Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥11.7B | ¥10.9B | ¥10.3B | ¥10.1B | ¥9.35B |
| Revenue growth | — | +6% | +2% | +8% | — |
| Gross profit | ¥7.53B | ¥7.21B | ¥6.97B | ¥7.04B | ¥6.70B |
| EBITDA | ¥6.32B | ¥6.05B | ¥5.96B | ¥6.09B | ¥5.29B |
| Net income | ¥4.12B | ¥3.90B | ¥3.79B | ¥3.97B | ¥3.37B |
| Free cash flow | n/a | ¥3.63B | ¥2.63B | ¥4.42B | ¥2.05B |
| Capital expenditure | n/a | ¥239M | ¥903M | ¥85.0M | ¥80.0M |
| Total debt | ¥39.0M | ¥102M | ¥120M | ¥165M | ¥133M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 368A.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.4% | -11.0% | 8th highest of 20 |
| 6-month return | -9.2% | -25.9% | 4th highest of 20 |
| Distance from 52-week high | -26.4% | -45.8% | 5th highest of 20 |
| Revenue growth (TTM) | +9.3% | -4.4% | 6th highest of 19 |
| Operating margin | 52.1% | 4.9% | highest of 20 |
| Forward P/E | 12.0× | 20.2× | cheapest of 4 |
| Growth the price implies (Req g, 7 yrs) | -16.7% | 10.1% | least demanding of 14 |
| Growth delivered (Del g) | +5.4% | +0.5% | 5th highest of 14 |
| Hurdle (Req g minus delivered) | -22.1 pp | +9.6 pp | 2nd least demanding of 14 |
| ROIC minus cost of capital | +56.5 pp | -5.7 pp | highest of 19 |
| EV / EBITDA | 5.7× | 12.3× | 2nd cheapest of 7 |
| Net debt / EBITDA | -2.2× | 2.5× | 2nd least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kitazato 368A.T | Japan | $317M | -9% | +9% | 52% | 12.0× | -16.7% | +5.4% |
| Zhejiang Shengda Bio-Pharm 603079.SS | China | $318M | -29% | -3% | 7% | n/a | 5.7% | -0.3% |
| Shandong Sito Bio-technology 300583.SZ | China | $318M | -26% | +19% | 6% | n/a | 2.7% | +2.3% |
| Swedencare SECARE.ST | Sweden | $315M | -23% | +3% | 7% | 23.4× | 5.5% | +62.1% |
| GC Corp. 005250.KS | South Korea | $319M | -32% | +10% | 1% | n/a | 31.5% | +7.4% |
| Eikon Therapeutics EIKN | United States | $320M | -41% | n/a | n/a | n/a | n/a | n/a |
| Ocugen OCGN | United States | $314M | -39% | -11% | -1,444% | n/a | n/a | n/a |
| Enanta Pharmaceuticals ENTA | United States | $320M | -28% | +1% | -90% | n/a | n/a | n/a |
| Zhejiang Zhenyuan Share 000705.SZ | China | $312M | -25% | -33% | -5% | n/a | n/a | n/a |
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $321M | +149% | +66% | 9% | n/a | n/a | n/a |
| 6467 6467.TW | Taiwan | $322M | n/a | n/a | -2,618% | n/a | n/a | n/a |
| Hainan Huluwa Pharmaceutical 605199.SS | China | $322M | -21% | -32% | -58% | n/a | 2.5% | -4.9% |
| Emergent BioSolutions EBS | United States | $312M | -27% | -18% | 5% | 16.1× | -0.1% | -13.7% |
| Solara Active Pharma Sciences SOLARA.NS | India | $323M | +23% | +27% | 8% | 20.2× | 37.7% | -3.2% |
| Shanxi C&Y Pharmaceutical 300254.SZ | China | $308M | -44% | -6% | 9% | n/a | 10.1% | +0.6% |
| Enwei Pharmaceutical 301331.SZ | China | $326M | -20% | -7% | 5% | n/a | 15.1% | +7.3% |
| Hangzhou Tianmushan Pharmaceutical Enterprise 600671.SS | China | $327M | -10% | -19% | 5% | n/a | 22.5% | +0.5% |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $328M | -38% | +10% | -8% | n/a | n/a | n/a |
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | 0% | +3% | 21% | n/a | -10.4% | +10.3% |
| Honz Pharmaceutical 300086.SZ | China | $330M | -35% | -23% | -54% | n/a | 58.0% | -12.8% |
| Chengdu Huasun Technology 000790.SZ | China | $333M | -22% | -36% | -57% | n/a | 28.5% | -6.4% |